Sökning: WFRF:(Swahn Eva) >
Dual Antithrombotic...
-
Cannon, Christopher P.Baim Institute for Clinical Research, USA; Brigham and Women’s Hospital, Heart and Vascular Center, USA; Harvard Medical School, USA,Baim Inst Clin Res, 930 Commonwealth Ave, Boston, MA 02215 USA.;Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Boston, MA USA.
(författare)
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
- Artikel/kapitelEngelska2017
Förlag, utgivningsår, omfång ...
-
Massachusetts Medical Society,2017
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-145511
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-145511URI
-
https://doi.org/10.1056/NEJMoa1708454DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-340755URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BACKGROUND: Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated with a high risk of bleeding.METHODS: inhibitor (clopidogrel or ticagrelor) and no aspirin (110-mg and 150-mg dual-therapy groups). Outside the United States, elderly patients (≥80 years of age; ≥70 years of age in Japan) were randomly assigned to the 110-mg dual-therapy group or the triple-therapy group. The primary end point was a major or clinically relevant nonmajor bleeding event during follow-up (mean follow-up, 14 months). The trial also tested for the noninferiority of dual therapy with dabigatran (both doses combined) to triple therapy with warfarin with respect to the incidence of a composite efficacy end point of thromboembolic events (myocardial infarction, stroke, or systemic embolism), death, or unplanned revascularization.RESULTS: The incidence of the primary end point was 15.4% in the 110-mg dual-therapy group as compared with 26.9% in the triple-therapy group (hazard ratio, 0.52; 95% confidence interval [CI], 0.42 to 0.63; P<0.001 for noninferiority; P<0.001 for superiority) and 20.2% in the 150-mg dual-therapy group as compared with 25.7% in the corresponding triple-therapy group, which did not include elderly patients outside the United States (hazard ratio, 0.72; 95% CI, 0.58 to 0.88; P<0.001 for noninferiority). The incidence of the composite efficacy end point was 13.7% in the two dual-therapy groups combined as compared with 13.4% in the triple-therapy group (hazard ratio, 1.04; 95% CI, 0.84 to 1.29; P=0.005 for noninferiority). The rate of serious adverse events did not differ significantly among the groups.CONCLUSIONS: inhibitor, and aspirin. Dual therapy was noninferior to triple therapy with respect to the risk of thromboembolic events. (Funded by Boehringer Ingelheim; RE-DUAL PCI ClinicalTrials.gov number, NCT02164864)
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Bhatt, Deepak L.Brigham and Women’s Hospital, Heart and Vascular Center, USA; Harvard Medical School, USA,Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Boston, MA USA.
(författare)
-
Oldgren, Jonas,1964-Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR),Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden(Swepub:uu)jonaoldg
(författare)
-
Lip, Gregory Y. H.Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK,Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England.
(författare)
-
Ellis, Stephen G.Cleveland Clin, Cleveland, OH 44106 USA.
(författare)
-
Kimura, TakeshiKyoto University, Department of Cardiovascular Medicine, Kyoto, Japan,Kyoto Univ, Dept Cardiovasc Med, Kyoto, Japan.
(författare)
-
Maeng, MichaelAarhus University Hospital, Skejby, Denmark,Aarhus Univ Hosp, Skejby, Denmark.,St Antonius Hosp, Nieuwegein, Netherlands.,St. Antonius Ziekenhuis, Nieuwegein, Netherlands
(författare)
-
Merkely, BelaUniversity Heart and Vascular Center, Budapest, Hungary,Univ Heart & Vasc Ctr, Budapest, Hungary.
(författare)
-
Zeymer, UweKlinikum der Stadt Ludwigshafen am Rhein, Medizinische Klinik B, Ludwigshafen, Germany
(författare)
-
Gropper, SavionBoehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.
(författare)
-
Nordaby, MatiasBoehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.
(författare)
-
Kleine, EvaBoehringer Ingelheim GmbH & Co KG, Ingelheim, Germany.
(författare)
-
Harper, RuthBoehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England.
(författare)
-
Manassie, JennyBoehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England.
(författare)
-
Januzzi, James L.Baim Institute for Clinical Research, USA; Cardiology Division, Massachusetts General Hospital, USA; Harvard Medical School, USA,Baim Inst Clin Res, 930 Commonwealth Ave, Boston, MA 02215 USA.;Harvard Med Sch, Boston, MA USA.;Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
(författare)
-
Ten Berg, Jurrien M.St. Antonius Ziekenhuis, Nieuwegein, Netherlands
(författare)
-
Steg, P. GabrielImperial College, London, London, UK,Imperial Coll, London, England.;Univ Paris Diderot, French Alliance Cardiovasc Trials, F CRIN Network, DHU FIRE,INSERM,Unite 1148, Paris, France.;Hop Bichat Assistance Publ, Paris, France.
(författare)
-
Hohnloser, Stefan H.Johann Wolfgang Goethe University, Department of Medicine, Division of Cardiology, Frankfurt am Main, Germany,Goethe Univ Frankfurt, Dept Med, Div Cardiol, Frankfurt, Germany.
(författare)
-
Swahn, Eva,1949-Linköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US,RE-DUAL PCI Steering Committee and Investigators(Swepub:liu)evasw45
(bidragsgivare)
-
Baim Institute for Clinical Research, USA; Brigham and Women’s Hospital, Heart and Vascular Center, USA; Harvard Medical School, USABaim Inst Clin Res, 930 Commonwealth Ave, Boston, MA 02215 USA.;Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, Boston, MA USA.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:New England Journal of Medicine: Massachusetts Medical Society377:16, s. 1513-15240028-47931533-4406
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Cannon, Christop ...
-
Bhatt, Deepak L.
-
Oldgren, Jonas, ...
-
Lip, Gregory Y. ...
-
Ellis, Stephen G ...
-
Kimura, Takeshi
-
visa fler...
-
Maeng, Michael
-
Merkely, Bela
-
Zeymer, Uwe
-
Gropper, Savion
-
Nordaby, Matias
-
Kleine, Eva
-
Harper, Ruth
-
Manassie, Jenny
-
Januzzi, James L ...
-
Ten Berg, Jurrie ...
-
Steg, P. Gabriel
-
Hohnloser, Stefa ...
-
Swahn, Eva, 1949 ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
New England Jour ...
- Av lärosätet
-
Linköpings universitet
-
Uppsala universitet